0001213900-23-041170.txt : 20230518 0001213900-23-041170.hdr.sgml : 20230518 20230518160511 ACCESSION NUMBER: 0001213900-23-041170 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230517 FILED AS OF DATE: 20230518 DATE AS OF CHANGE: 20230518 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Broder Samuel CENTRAL INDEX KEY: 0001340543 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40410 FILM NUMBER: 23936042 MAIL ADDRESS: STREET 1: C/O SENSEI BIOTHERAPEUTICS, INC. STREET 2: 1405 RESEARCH DR., STE. 125 CITY: ROCKVILLE STATE: MD ZIP: 20850 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Orion Biotech Opportunities Corp. CENTRAL INDEX KEY: 0001847416 STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770] IRS NUMBER: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE VANDERBILT AVENUE, 26TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10017 BUSINESS PHONE: 212-303-7822 MAIL ADDRESS: STREET 1: ONE VANDERBILT AVENUE, 26TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10017 4 1 ownership.xml X0407 4 2023-05-17 1 0001847416 Orion Biotech Opportunities Corp. ORIA 0001340543 Broder Samuel C/O ORION BIOTECH OPPORTUNITIES CORP. ONE VANDERBILT AVENUE, 26TH FLOOR NEW YORK NY 10017 1 0 0 0 0 Class B ordinary shares 2023-05-17 4 D 0 40000 0.00 D Class A ordinary shares 40000 0 D On April 21, 2023, the Issuer announced that it will not consummate an initial business combination within the time period required. Pursuant to the Issuer's Amended and Restated Memorandum and Articles of Association (the "Articles") and in connection with the winding up of the Issuer, the Class B ordinary shares, par value $0.0001, held by the Reporting Person were surrendered for no compensation on May 17, 2023. After giving effect to the Issuer's delisting and deregistration, the Reporting Person will no longer be subject to Section 16 reporting obligations. /s/ Marcello Liguori, as attorney in fact for Samuel Broder 2023-05-18